Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 8
Submit an article Journal homepage
168
Views
29
CrossRef citations to date
0
Altmetric
Review

Carbamylated erythropoietin to treat neuronal injury: new development strategies

Paul A Lapchak University of California San Diego, Department of Neurosciences, MTF 316, 9500 Gilman Drive, La Jolla, CA 92093-0624, USA +1 858 822 1297; +1 858 822 4106; [email protected]; VASDHS Stroke Research, San Diego, California, USA; Veterans Medical Research Foundation, San Diego, California, USA
, PhD
Pages 1175-1186 | Published online: 10 Jul 2008

Bibliography

  • Egrie J. The cloning and production of recombinant human erythropoietin. Pharmacotherapy 1990;10(2(Pt 2)):S3-8
  • Browne JK, Cohen AM, Egrie JC, et al. Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol 1986;51(Pt 1):693-702
  • Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82(22):7580-4
  • Han F, Wu S, Xue S, et al. Cloning of the human erythropoietin exons and their expression in COS-7 cells. Chin J Biotechnol 1996;12(4):227-33
  • Maouche L, Tournamille C, Hattab C, et al. Cloning of the gene encoding the human erythropoietin receptor. Blood 1991;78(10):2557-63
  • Gurney CW. Erythropoietin. Adv Metab Disord 1968;3:279-304
  • Gosselin G, Colpron G, Long LA. The kidney and erythropoietin. Union Med Can 1965;94(12):1591-603
  • Lange RD, Pavlovic-Kentera V. Erythropoietin. Prog Hematol 1964;27:72-96
  • Littlewood T. Medical uses of erythropoietin. Vox Sang 2004;87(Suppl 2):93-5
  • Liberato NL, Costa A, Barosi G. Erythropoietin: biological aspects and clinical usefulness. Haematologica 1990;75(4):346-62
  • Varet B, Casadevall N, Lacombe C, Nayeaux P. Erythropoietin: physiology and clinical experience. Semin Hematol 1990;27(3 Suppl 3):25-31
  • Erslev AJ, Schuster SJ, Caro J. Erythropoietin and its clinical promise. Eur J Haematol 1989;43(5):367-73
  • Graber SE, Krantz SB. Erythropoietin: biology and clinical use. Hematol Oncol Clin North Am 1989;3(3):369-400
  • Urabe A, Kitamura T, Takaku F. Clinical application of erythropoietin. Nippon Ketsueki Gakkai Zasshi 1988;51(8):1355-9
  • Krantz SB. Editorial: recent contributions to the mechanism of action and clinical relevance of erythropoietin. J Lab Clin Med 1973;82(6):847-57
  • Epogen. Available from: www.epogen.com
  • Procrit. Available from: www.procrit.com
  • Aranesp. Available from: www.aranesp.com
  • Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol 2008;141(3):287-97
  • Koide K, Arai T. Erythropoietin – complications, side effects. Nippon Rinsho 1991;49(Suppl):679-87
  • Bennett WM. Side effects of erythropoietin therapy. Am J Kidney Dis 1991;18(4 Suppl 1):84-6
  • Samtleben W, Ehmer B, Lutz-Knochenhauer I, et al. Side effects during recombinant human erythropoietin therapy in 2,000 ESRD patients. Contrib Nephrol 1991;88:107-16; discussion 117
  • Gretz N, Lasserre J, Kraft K, et al. Efficacy and side effects of erythropoietin used in the treatment of anemia of uremic rats. Contrib Nephrol 1988;60:236-44
  • Gretz N, Lasserre JJ, Meisinger E, et al. Potential side-effects of erythropoietin. Lancet 1987;1(8523):46
  • Warren Pharmaceuticals (Pharmaceuticals W). Novel carbamylated epo and method for its production. WO2006/014466
  • Kitamura T, Tange T, Terasawa T, et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989;140(2):323-34
  • Kitamura T, Tojo A, Kuwaki T, et al. Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood 1989;73(2):375-80
  • Available from: www.ATCC.org
  • Migliaccio AR, Jiang Y, Migliaccio G, et al. Transcriptional and posttranscriptional regulation of the expression of the erythropoietin receptor gene in human erythropoietin-responsive cell lines. Blood 1993;82(12):3760-9
  • Miura Y, Komatsu N, Suda T. Growth and differentiation of two human megakaryoblastic cell lines; CMK and UT-7. Prog Clin Biol Res 1990;356:259-70
  • Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305(5681):239-42
  • Jacobson GR, Stark GR. Aspartate transcarbamylase of Escherichia coli. Mechanisms of inhibition and activation by dicarboxylic acids and other anions. J Biol Chem 1975;250(17):6852-60
  • Hammes GG, Porter RW, Stark GR. Relaxation spectra of aspartate transcarbamylase. Interaction of the catalytic subunit with carbamyl phosphate, succinate, and L-malate. Biochemistry 1971;10(6):1046-50
  • Hammes GG, Wu CW. Relaxation spectra of aspartate transcarbamylase. Interaction of the native enzyme with carbamyl phosphate. Biochemistry 1971;10(11):2150-6
  • Stark GR. Reactions of cyanate with functional groups of proteins. IV. Inertness of aliphatic hydroxyl groups. Formation of carbamyl- and acylhydantoins. Biochemistry 1965;4(11):2363-7
  • Zeng J. Lysine modification of metallothionein by carbamylation and guanidination. Methods Enzymol 1991;205:433-7
  • Mun KC, Golper TA. Impaired biological activity of erythropoietin by cyanate carbamylation. Blood Purif 2000;18(1):13-7
  • Satake R, Kozutsumi H, Takeuchi M, Asano K. Chemical modification of erythropoietin: an increase in in vitro activity by guanidination. Biochim Biophys Acta 1990;1038(1):125-9
  • Pedersen LO, Stryhn A, Holter TL, et al. The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m. Eur J Immunol 1995;25(6):1609-16
  • Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8(8):495-505
  • Stroke intervention in clinical trials. Erythropoietin beta (EPO),recombinant human EPO (rhEPO), Phase II study. The Internet Stroke Center at Washington Univeristy St. Louis, 2005. Trial information. Available from: www.strokecenter.org/trials/InterventionDetail.aspx?tid=200
  • Ehrenreich H, Aust C, Krampe H, et al. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 2004;19(3-4):195-206
  • Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 2004;22(2):105-19
  • Genc S, Koroglu TF, Genc K. Erythropoietin and the nervous system. Brain Res 2004;1000(1-2):19-31
  • Hoke A, Keswani SC. Neuroprotection in the PNS: erythropoietin and immunophilin ligands. Ann NY Acad Sci 2005;1053:491-501
  • McPherson RJ, Juul SE. Recent trends in erythropoietin-mediated neuroprotection. Int J Dev Neurosci 2008;26(1):103-11
  • Grasso G, Sfacteria A, Meli F, et al. The role of erythropoietin in neuroprotection: therapeutic perspectives. Drug News Perspect 2007;20(5):315-20
  • Grasso G. Erythropoietin: a new paradigm for neuroprotection. J Neurosurg Anesthesiol 2006;18(2):91-2
  • Milano M, Collomp R. Erythropoietin and neuroprotection: a therapeutic perspective. J Oncol Pharm Pract 2005;11(4):145-9
  • Roesler R, Quevedo J, Schroder N. Erythropoietin, glutamate, and neuroprotection. N Engl J Med 2004;351(14):1465-6; author reply 1465-1466
  • Villa P, van Beek J, Larsen AK, et al. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 2007;27(3):552-63
  • Wang Y, Zhang ZG, Rhodes K, et al. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 2007;151(8):1377-84
  • Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53(6):743-51
  • Lapchak Pask, Kirkeby A, Sager T. Nonerythropoietic carbamylerythropoietin improves clinical rating scores and motor function in embolized rabbits following multiple infarct ischemic strokes: a therapeutic window study. America Heart Association Conference, San Francisco, CA; 2007
  • Ingall T. Stroke – incidence, mortality, morbidity and risk. J Insur Med 2004;36(2):143-52
  • NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):1581-7
  • Zivin JA, Fisher M, DeGirolami U, et al. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985;230(4731):1289-92
  • Zivin JA, Lyden PD, DeGirolami U, et al. Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke. Arch Neurol 1988;45(4):387-91
  • Lapchak PA, Araujo DM. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs 2007;12(1):97-112
  • Lapchak PA, Araujo DM, Song D, et al. Neuroprotective effects of the spin trap agent disodium-[(tert- butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 2002;33(5):1411-5
  • Lapchak PA, Araujo DM, Zivin JA. Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol 2004;185(1):154-9
  • Lapchak PA, Salgado KF, Chao CH, Zivin JA. Transcranial near-infrared light therapy improves motor function following embolic strokes in rabbits: an extended therapeutic window study using continuous and pulse frequency delivery modes. Neuroscience 2007;148(4):907-14
  • Lapchak PA, Wei J, Zivin JA. Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. Stroke 2004;35(8):1985-8
  • Lapchak PA, Araujo DM, Pakola S, et al. Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke 2002;33:2279-84
  • Lapchak PA, Song D, Wei J, Zivin JA. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp Neurol 2004;188(2):279-85
  • Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs 2002;11(11):1623-32
  • Dietz V, Curt A. Neurological aspects of spinal-cord repair: promises and challenges. Lancet Neurol 2006;5(8):688-94
  • Fawcett JW, Curt A, Steeves JD, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007;45(3):190-205
  • Steeves JD, Lammertse D, Curt A, et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 2007;45(3):206-21
  • Tuszynski MH, Steeves JD, Fawcett JW, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics. Spinal Cord 2007;45(3):222-31
  • Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995;12(1):1-21
  • King VR, Averill SA, Hewazy D, et al. Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur J Neurosci 2007;26(1):90-100
  • Mennini T, De Paola M, Bigini P, et al. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med 2006;12(7-8):153-60
  • Rathke-Hartlieb S, Schmidt VC, Jockusch H, et al. Spatiotemporal progression of neurodegeneration and glia activation in the wobbler neuropathy of the mouse. Neuroreport 1999;10(16):3411-6
  • Schmitt-John T, Drepper C, Mussmann A, et al. Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the wobbler mouse. Nat Genet 2005;37(11):1213-5
  • Greene KA, Marciano FF, Sonnag VKH. Pharmacological management of spinal cord injury: current status of drugs designed to augment functional recovery of the injured human spinal cord. J Spinal Disorders 1996;9:355-66
  • Hogue CW, Sundt TM, Goldberg M, et al. Neurological complications of cardiac surgery: the need for new paradigms in prevention and treatment. Semi Thorac Cardiovasc Surg 1999;11(2):105-15
  • Hollier LH. Causes and prevention of spinal cord ischemia. In: Veith FJ, editor, Current critical problems in vascular surgery. Quality Medical Publishing: St. Louis; 1990
  • Hollier LH, Moore WM. Avoidance of renal and neurologic complications following thoracoabdominal aortic aneurysm repair. Acta Chir Scand Suppl 1990;555:129-35
  • Kouchoukos NT. Spinal cord ischemic injury: Is it preventable. Sem Thorac Cardiovas Surg 1991;3:323-8
  • Koudsi B, Yu CD, Ferguson EW, et al. Prevention of spinal cord injury after transient aortic clamping with tissue factor pathway inhibitor. Surgery 1996;119:269-74
  • Mahmood A, Lu D, Qu C, et al. Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J Neurosurg 2007;107(2):392-7
  • McNett M. A review of the predictive ability of Glasgow Coma Scale scores in head-injured patients. J Neurosci Nurs 2007;39(2):68-75
  • Ashman TA, Gordon WA, Cantor JB, Hibbard MR. Neurobehavioral consequences of traumatic brain injury. Mt Sinai J Med 2006;73(7):999-1005
  • Schwab KA, Ivins B, Cramer G, et al. Screening for traumatic brain injury in troops returning from deployment in Afghanistan and Iraq: initial investigation of the usefulness of a short screening tool for traumatic brain injury. J Head Trauma Rehabil 2007;22(6):377-89
  • Warden D. Military TBI during the Iraq and Afghanistan wars. J Head Trauma Rehabil 2006;21(5):398-402
  • Sayer NA, Chiros CE, Sigford B, et al. Characteristics and rehabilitation outcomes among patients with blast and other injuries sustained during the Global War on Terror. Arch Phys Med Rehabil 2008;89(1):163-70
  • Kiraly M, Kiraly SJ. Traumatic brain injury and delayed sequelae: a review – traumatic brain injury and mild traumatic brain injury (concussion) are precursors to later-onset brain disorders, including early-onset dementia. ScientificWorldJournal 2007;7:1768-76
  • Helmy A, Vizcaychipi M, Gupta AK. Traumatic brain injury: intensive care management. Br J Anaesth 2007;99(1):32-42
  • Jakobsen J. Axonal dwindling in early experimental diabetes. II. A study of isolated nerve fibres. Diabetologia 1976;12(6):547-53
  • Jakobsen J. Axonal dwindling in early experimental diabetes. I. A study of cross sectioned nerves. Diabetologia 1976;12(6):539-46
  • Jakobsen J, Lundbaek K. Neuropathy in experimental diabetes: an animal model. Br Med J 1976;2(6030):278-9
  • Sidenius P, Jakobsen J. Retrograde axonal transport. A possible role in the development of neuropathy. Diabetologia 1981;20(2):110-2
  • Weiss RB. Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat Rep 1982;66(3):427-38
  • Kolb H. Mouse models of insulin dependent diabetes: low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes Metab Rev 1987;3(3):751-78
  • Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol 1999;41(Suppl 1):8-13
  • Fox A, Eastwood C, Gentry C, et al. Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain 1999;81(3):307-16
  • Schmidt RE, Scharp DW. Axonal dystrophy in experimental diabetic autonomic neuropathy. Diabetes 1982;31(9):761-70
  • Schmidt RE, Green KG, Feng D, et al. Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice. Exp Neurol 2008;209(1):161-70
  • Said G. Diabetic neuropathy – a review. Nat Clin Pract Neurol 2007;3(6):331-40
  • Hornick T, Aron DC. Preventing and managing diabetic complications in elderly patients. Cleve Clin J Med 2008;75(2):153-8
  • Pulido JE, Pulido JS, Erie JC, et al. A role for excitatory amino acids in diabetic eye disease. Exp Diabetes Res 2007;2007:36150
  • Baxter AG. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 2007;7(11):904-12
  • Lassmann H. Experimental models of multiple sclerosis. Rev Neurol (Paris) 2007;163(6-7):651-5
  • Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006;60(1):12-21
  • Savino C, Pedotti R, Baggi F, et al. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol 2006;172(1-2):27-37
  • Bolton C. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis. Inflammopharmacology 2007;15(5):183-7
  • Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol 2007;62(4):314-26
  • Muraro PA, Bielekova B. Emerging therapies for multiple sclerosis. Neurotherapeutics 2007;4(4):676-92
  • Shah A, Eggenberger E, Zivadinov R, et al. Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects. Neurotherapeutics 2007;4(4):627-32
  • Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249(1):9-17
  • Cano JR, Catalan B, Jara C. Neuronopathy due to cisplatin. Rev Neurol 1998;27(158):606-10
  • Gastaut JL, Pellissier JF, Jean P, et al. Cis-platinum-induced peripheral neuropathy. One case (author's transl). Nouv Presse Med 1982;11(15):1113-7
  • Greenspan A, Treat J. Peripheral neuropathy and low dose cisplatin. Am J Clin Oncol 1988;11(6):660-2
  • Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992;10(5):795-803
  • Thompson SW, Davis LE, Kornfeld M, et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984;54(7):1269-75
  • Bianchi R, Brines M, Lauria G, et al. Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res 2006;12(8):2607-12
  • Jones J, Jang S, Getch CC, et al. Advances in the radiosurgical treatment of large inoperable arteriovenous malformations. Neurosurg Focus 2007;23(6):E7
  • Chen AM, Jahan TM, Jablons DM, et al. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer 2007;109(8):1668-75
  • Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12(7):884-98
  • Hussain A, Brown PD, Stafford SL, Pollock BE. Stereotactic radiosurgery for brainstem metastases: survival, tumor control, and patient outcomes. Int J Radiat Oncol Biol Phys 2007;67(2):521-4
  • Friehs GM, Park MC, Goldman MA, et al. Stereotactic radiosurgery for functional disorders. Neurosurg Focus 2007;23(6):E3
  • Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 2003;4(9):529-36
  • Coleman CN, Blakely WF, Fike JR, et al. Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17-18, 2001. Radiat Res 2003;159(6):812-34
  • Jones B, Hopewell JW, Dale RG. Radiobiological compensation for unintended treatment interruptions during palliative radiotherapy. Br J Radiol 2007;80(960):1006-10
  • Hopewell JW, Millar WT, Ang KK. Toward improving the therapeutic ratio in stereotactic radiosurgery: selective modulation of the radiation responses of both normal tissues and tumor. J Neurosurg 2007;107(1):84-93
  • Erbayraktar S, de Lanerolle N, de Lotbiniere A, et al. Carbamylated erythropoietin reduces radiosurgically-induced brain injury. Mol Med 2006;12(4-6):74-80
  • Zeigler ZR, Rosenfeld CS, Shadduck RK. Resolution of transfusion dependence by recombinant human erythropoietin (rHuEPO) in acquired pure red cell aplasia (PRCA) associated with myeloid metaplasia. Br J Haematol 1993;83(1):28-9
  • Evens AM, Bennett CL, Luminari S. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. Best Pract Res Clin Haematol 2005;18(3):481-9
  • Indiveri F, Murdaca G. Immunogenicity of erythropoietin and other growth factors. Rev Clin Exp Hematol 2002;(Suppl 1):7-11
  • Noguchi A, Mukuria CJ, Suzuki E, Naiki M. Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. J Biochem 1995;117(1):59-62
  • Kharagjitsingh AV, Korevaar JC, Vandenbroucke JP, et al. Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int 2005;68(3):1215-22
  • Lapchak PA. NXY-059. Centaur. Curr Opin Investig Drugs 2002;3(12):1758-62
  • Lapchak PA. Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Rev Neurosci 1996;7(3):165-76
  • Lapchak PA, Araujo DM. Advances in hemorrhagic stroke therapy: conventional and novel approaches. Expert Opin Emerg Drugs 2007;12(3):389-406
  • Debens T. Technology evaluation: desmoteplase, PAION/Forest. Curr Opin Mol Ther 2004;6(5):567-75
  • Schleuning WD. Vampire Bat Plasminogen Activator DSPA-Alpha-1 (Desmoteplase): a thrombolytic drug optimized by natural selection. Haemostasis 2001;31(3):118-22
  • O'Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59(3):467-77
  • Lyden PD, Lees KR, Davis SM. Alteplase for acute stroke revisited: the first 10 years. Lancet Neurol 2006;5(9):722-4
  • Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357(6):562-71
  • Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354(6):588-600
  • NCT00119626 and NCT00061022. Available from: www.ClinicalTrials.gov
  • Aviailable from: www.strokecenter.org/trials/scales

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.